China's liver cancer treatment ushered in a new dawn, the epoch-making treatment pattern is coming.

The 2020 edition of the Chinese Society of Clinical Oncology (CSCO) Primary Liver Cancer Diagnosis and Treatment Guidelines was officially released on July 18, 2020, Shanghai - Since the "Healthy China Strategy" was proposed, the level of cancer diagnosis and clinical research in China has steadily improved, and standardized diagnosis and treatment has received more and more attention. On
18, the Chinese Society of Clinical Oncology (CSCO) held a press conference to officially announce the high-profile 2020 edition of the CSCO Primary Liver Cancer Diagnosis and Treatment Guide (hereinafter referred to as the "Guideline"). Professor Qin Shuxuan, Director of the Oncology Center of Jinling Hospital, Nanjing
, Vice Chairman of CSCO Liver Cancer Expert Committee, Professor Zhou Jian, Vice President of Zhongshan Hospital affiliated with Fudan University, Chairman of the Committee of the Liver Cancer Professional Committee of the China Anti-Cancer Association, Director of Hepatobiliary Surgery, Director of the Committee of Experts on CSCO Liver Cancer, Vice President of Zhejiang University Medical School Professor Pan Hongming, Standing Member of the CSCO Committee of Experts on Liver Cancer, Dr. Zhai Weidong, Director of Hepatobiliary Surgery at the First Hospital affiliated with The University of Science and Technology of China, Professor Weidong, Deputy Director of the Oncology Department of Nanjing Jinling Hospital, And Professor Liu Xiufeng, Secretary-General of the CSCO Committee of Experts on Liver Cancer, attended the meeting to witness the opening of a new chapter in the diagnosis and treatment of liver cancer in China.
"King of Cancer": China's liver cancer is the fourth common malignant tumor and the second fatal cause of cancer in China, including hepatocellular cancer (HCC), intra-hepatic bile duct cancer (ICC) and HCC-ICC mixed 3 different pathology types, of which HCC accounted for 85% to 90%.
750,000 new cases of hepatocellular carcinoma worldwide each year1, most of which come from Asia, and almost half of them from China2.
According to the 2015 China Annual Report on Oncology, there are about 370,000 new cases of hepatocellular carcinoma in China each year, and 326,000 patients lose their lives as a result. Professor
, Professor Qin Shuxuan, pointed out that, unlike in Europe and the United States, liver cancer in China has a high degree of heterogeneity in its pathogenesis, epidemiological characteristics, molecular biology behavior, clinical manifestations and stages, as well as treatment strategies.
, therefore, China's liver cancer prevention and treatment is facing many difficulties. first,
, liver cancer is hidden, early symptoms are not obvious or typical, early diagnosis is very difficult;
because the rate of early screening of liver cancer in China is not high, about 85% of Chinese patients are already in the middle and late stage of treatment, lost the best treatment time. according to statistics
, among new liver cancer patients, advanced patients accounted for 58%, advanced hepatocellular carcinoma patients in the median survival of about 10 months, 5-year survival rate of only about 12%, with Europe, the United States or Japan and other Asian countries significantly different.
liver cancer treatment is currently facing a great unmet demand, the majority of patients look forward to a more safe and effective innovative treatment to significantly improve the life cycle and quality of life.
Professor Qin Shuxuan "Healthy China 2030": The importance of early screening, early diagnosis and early treatment of tumors has increased significantly since the "Healthy China 2030" Outline was put forward. The "Opinions on the Implementation of Healthy China Action" issued by the
in 2019 also sets out the requirements for the implementation of cancer prevention and control actions, and the target of a five-year survival rate of no less than 43.3% and 46.6% for cancer by 2022 and 2030, respectively, which fully reflects the high priority attached by the Party and the government to people's health and cancer prevention and control.
Since 2016, the Chinese Society of Oncology Clinical Society (CSCO) has issued a series of guidelines for malignant tumors, effectively guiding Chinese oncologists to carry out clinical practice, with a wide range of academic influence.
, cSCO primary liver cancer diagnosis and treatment guide has become an important reference for the diagnosis and treatment of liver cancer in China. The 2020 edition of the Guidelines, released by the
, is a supplement and refinement of the 2019 National Health And IHC Guidelines for the Diagnosis and Treatment of Primary Liver Cancer, while incorporating the latest advances in evidence-based medicine and updating innovative treatment concepts. Professor Zhou Jian,
, said that the 2020 edition of the Guide not only added a number of targets, immunotherapy drugs and joint treatment options in the field of first-line and second-line treatment of liver cancer, but also increased the composition and discussion of multidisciplinary collaboration of mDT in liver cancer diagnosis and treatment; In addition,
, immunotherapy in the field of postoperative assisted therapy has been adjusted, and corresponding indications are expanded and updated in the field of intervention, radiotherapy and ablation, and antiviral therapy of hepatitis-related liver cancer patients who are very concerned has been revised in this update.
on the whole, the new edition of the Guide is of great significance for improving the level of clinicians' diagnosis and treatment and promoting the standardized diagnosis and treatment of primary liver cancer.
update the treatment concept: Innovative immunotherapy has attracted much attention to CSCO not only drawing on foreign advanced experience in the development of guidelines, but also emphasizing the clinical research of Chinese scholars.
in the field of targeted therapy, thanks to advances in precision medicine, advances in precision diagnostics and precision therapy, and on-target drugs, especially for clearer molecular dye types and in-depth research on driving genes.
multi-target, multikinase inhibitor, Doafini, is one of the first-line I-level expert recommendations (1A evidence) for this update. Professor shen Feng,
, is the focus of global cancer treatment, related research is in full swing, the joint program of the exploration of liver cancer patients has brought new hope.
because of its small side effects and obvious therapeutic effect, immunotherapy is gradually becoming the future development direction of tumor treatment, known as the fourth major tumor treatment technology after surgery, radiotherapy and chemotherapy. Professor
Qin Shuxuan said that the new edition of the Guide, another new first-line I-level expert recommendation (1A evidence) - Atalizhu zuma anti-combination belavzumab immune combination treatment program has a new mechanism of action, through large sample clinical trials to fully demonstrate that first-line treatment can significantly reduce the risk of death of patients with advanced non-surgical excision of liver cell cancer, and significantly improve the quality of life.
has previously been NCCN, ESMO and other international well-known guidelines as a first-line recommendation.
In addition, the Karelli Beads Mono-Anti-Joint O'Shaliplatin-based system chemotherapy, as well as The Karili Beads Monita-Combined Apatini, are also included in the guidelines For First Class III recommendations.
at the same time, taking into account the high risk of postoperative recurrence in some patients, future treatment will be extended from the advanced first line to auxiliary treatment and even new auxiliary treatment, explore how to reduce relapse metastasis after surgery, radiotherapy, and improve the removal rate of surgery by improving preoperative treatment options. Professor Pan Hongming,
, multidisciplinary collaboration: the composition and discussion of the clinical multidisciplinary collaboration team (MDT) in optimizing the new model of liver cancer diagnosis and treatment is also one of the highlights of the update of the Guide.
MDT is the internationally recognized mainstream diagnosis and treatment model in the field of cancer, and has also become the standard mode and important means in the diagnosis and treatment system of advanced liver cancer, which can effectively help patients with advanced liver cancer to choose the most suitable treatment plan, achieve optimal personalized comprehensive treatment and bring clinical benefits. Professor Zhou Jian,
, said that the MDT diagnosis and treatment model can play a multidisciplinary collaboration in the relevant departments in the field of liver cancer diagnosis and treatment, avoid the limitations of single-disciplinary diagnosis and treatment, is conducive to the selection of reasonable treatment methods and drugs, in the requirement to follow high-level evidence of evidence-based evidence at the same time consider the individualfactory of patients. Professor Liu Xiufeng,
, "CSCO primary liver cancer diagnosis and treatment guide" since its launch in 2018, at an annual rate to maintain updates, not only in line with the latest trends in the field of international liver cancer, but also in line with the national conditions, fully reflect the Chinese characteristics of liver cancer diagnosis and treatment.
future, the CSCO Committee of Experts on Liver Cancer will continue to actively implement the national policy and policy on health reform and development, broadly unite and organize the vast number of liver cancer clinical oncologists and related units, and jointly improve the level of academic research on liver cancer diagnosis and treatment in China, and promote the standardization, standardization, specialization and individualization of liver cancer diagnosis and treatment.
References: 1. World Health Organization: Globocan 2018 - Liver Cancer factsheet. (Internet; cited 2020 Jan) Availablefrom: Health Organization: Globocan 2018 - China factsheet. (Internet; cited 2020 Jan) Availablefrom: